ISB News

The Rise of Open Proteomics

Researchers at EMBL-EBI, Institute for Systems Biology and other partnering organizations have launched ProteomeXchange, a public portal for exchanging proteomics data generated from mass-spectrometry experiments and other related information. From the EMBL-EBI-issued press release:

Eric Deutsch, head of PeptideAtlas at the Institute for Systems Biology in the U.S., says: “I’m certain that the ProteomeXchange system is already leading to greater awareness and reuse of publicly available datasets. I’m regularly contacted by people who want to explore new data they’ve heard about through our alert system, and am pleased to see so much growth in this area of science.” Read full press release.

As part of the launch, the consortium also published a correspondence piece in Nature Biotechnology (published online on March 10, 2014). An excerpt:

"There is a growing trend toward public dissemination of proteomics data, which is facilitating the assessment, reuse, comparative analyses and extraction of new findings from published data. This process has been mainly driven by journal publication guidelines and funding agencies. However, there is a need for better integration of public repositories and coordinated sharing of all the pieces of information needed to represent a full mass spectrometry (MS)–based proteomics experiment. …In this Correspondence, we report the first implementation of the ProteomeXchange consortium, an integrated framework for submission and dissemination of MS-based proteomics data."  Read full text.

Recent Articles

  • Building a Better BMI

    ISB researchers have constructed biological body mass index (BMI) measures that offer a more accurate representation of metabolic health and are more varied, informative and actionable than the traditional, long-used BMI equation. The work was published in the journal Nature Medicine. 

  • How Immune Cells ‘See’ and Respond to Mutations in Cancer Cells

    In a just-published paper in the journal Nature, a collaborative team of researchers from ISB, UCLA, PACT Pharma, and beyond analyzed T-cell responses in melanoma patients who were treated with different immune checkpoint inhibitors, and how those responses evolved over time.

  • Spotlight on ISB Education graphic

    2022-23 School Year ISB Education Highlights

    From planning, creating and executing workshops for educators to forging new relationships to elevate students, the ISB Education team has been in high gear. Each month throughout the 2022-2023 academic year, we will highlight some of the top projects the team is working on.